David Siegel, M.D., Ph.D.
The Division of Multiple Myeloma is headed by hematologist/oncologist David S. Siegel, M.D., Ph.D., one of the nation’s leading authorities on multiple myeloma. Dr. Siegel has more than 25 years of significant clinical and research expertise in treating and managing multiple myeloma.
Dr. Siegel received his medical degree from The New York University School of Medicine and a master’s degree and doctorate in immunology from The New York University Graduate School of Arts and Sciences Sackler Institute of Basic Medical Sciences. He completed a residency in internal medicine at New York University/Bellevue Medical Center and a fellowship in hematology/oncology at Memorial Sloan-Kettering Cancer Center, in New York City. Prior to joining The Cancer Center at Hackensack University Medical Center in 2002, Dr. Siegel was on the faculty of Memorial Sloan-Kettering Cancer Center, The University of Arkansas Cancer Research Center, and Atlantic Health System’s Stem Cell Transplantation Program.
Dr. Siegel has devoted most of his clinical and research career to the diagnosis, treatment, and management of multiple myeloma. He is one of a handful of physicians in the United States who have such specialized expertise in caring for patients with this disease. He is one of 11 investigators nationwide who have brought the exciting new chemotherapeutic agent Velcade to the treatment of multiple myeloma. He has also been involved in clinical trials for Revimid, a new chemotherapeutic agent, and Xcytes, T cells that are produced to accelerate blood cell recovery after stem cell transplantation.
WM Clinical Trials: https://clinicaltrials.gov/ct2/results?term=Siegel+Waldenstrom%27s